Category Archives: Parkinson’s Treatment

PUBLIC RELEASE DATE: 4-May-2014 Contact: Meng Zhao eic@nrren.org 86-138-049-98773 Neural Regeneration Research Levodopa is the preferred treatment for Parkinson's disease in the clinic. However, long-term use of levodopa may lead to various motor complications, among which levodopa-induced dyskinesia is the most common, severely affecting patients' quality of life. Dr. Jiancheng He and co-workers from Shanghai University of Traditional Chinese Medicine in China established a model of Parkinson's disease dyskinesia in rats, and treated these animals with Compound Formula Rehmannia. They found that Compound Formula Rehmannia alleviates levodopa-induced dyskinesia in Parkinson's disease by modulating neurotransmitter signaling in the corpus striatum. The relevant article has been published in the Neural Regeneration Research (Vol. 9, No. 4, 2014). ### Article: " Compound Formula Rehmannia alleviates levodopa-induced dyskinesia in Parkinson's disease," by Long Teng, Fang Hong, Chenguang Zhang, Jiancheng He, Haiying Wang (Shanghai University of Traditional Chinese Medicine, Shanghai, China) Teng L, Hong F, Zhang CG, He JC, Wang HY. Compound Formula Rehmannia alleviates levodopa-induced dyskinesia in Parkinson's disease. Neural Regen Res. 2014;9(4):407-412. Contact: Meng Zhao eic@nrren.org 86-138-049-98773 Neural Regeneration Research http://www.nrronline.org/ AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use … Continue reading →

Watch above: a respected voice on Parkinsons disease says newly diagnosed patients are benefiting from treatment advancements SASKATOON A University of Saskatchewan researcher says that a lot has changed about Parkinsons disease over the decades. In the 1950s and 60s, patients were diagnosed with Parkinsons, they lived less than ten years after their [diagnosis], said Dr. Ali Rajput, whos been studying the disease for over 40 years. People are now living close to a normal life span; maybe a couple years shorter, said Rajput. Parkinsons disease is a degenerative, movement disorder. Rajput said there are five stages to the disease; patients can experience symptoms that range from only affecting one side of the body, to being bedridden or wheelchair bound. The advancements in treatment of Parkinsons are good news for Elaine Gilbert, a newly diagnosed patient who learned the news on April Fools Day. I said youre kidding, youre joking right, its April fools, said Gilbert, a retired elementary school teacher. Elaine joins her husband, Malcolm, who has been battling the disease for around 15 years. Her Parkinsons is in its preliminary stages, which will allow doctors to properly formulate a plan of action. If you treat [Parkinsons] too late, … Continue reading →

Parkinson's Treatment - April 28th It's Parkinson's Awareness Month. Health Specialist Leah Sarich is here now with a new treatment option for late stage Parkinson's patients. By: citytvofficial … Continue reading →

A trio of studies from the Perelman School of Medicine at the University of Pennsylvania demonstrate new approaches to understanding, treating and potentially staving off Parkinson's disease (PD). Studies show that factors such as estrogen exposure and statin use have an impact on the onset of Parkinson's disease. And a new look at telemedicine demonstrates feasibility in providing care for Parkinson's patients using remote video visits to expand access and center care around the needs of Parkinson's patients. These studies and more will be presented at the American Academy of Neurology's 66th Annual Meeting at Philadelphia's Pennsylvania Convention Center from April 26 to May 3, 2014. "Researchers at Penn Medicine are looking at Parkinson's disease from all angles -- ways to improve treatment methods for those currently battling the disease, understanding the root causes of disease, and identifying potential interventions to delay the onset of disease," said Matthew Stern, MD, professor of Neurology in the Perelman School of Medicine at the University of Pennsylvania and director of Penn's Parkinson's Disease and Movement Disorders Center. "We are persistent and eager to find better targets and treatments to help patients with Parkinson's disease, which affects up to 1 million Americans and 10 … Continue reading →

PUBLIC RELEASE DATE: 27-Apr-2014 Contact: Kim Menard kim.menard@uphs.upenn.edu 215-200-2312 University of Pennsylvania School of Medicine PHILADEPHIA- A trio of studies from the Perelman School of Medicine at the University of Pennsylvania demonstrate new approaches to understanding, treating and potentially staving off Parkinson's disease (PD). Studies show that factors such as estrogen exposure and statin use have an impact on the onset of Parkinson's disease. And a new look at telemedicine demonstrates feasibility in providing care for Parkinson's patients using remote video visits to expand access and center care around the needs of Parkinson's patients. These studies and more will be presented at the American Academy of Neurology's 66th Annual Meeting at Philadelphia's Pennsylvania Convention Center from April 26 to May 3, 2014. "Researchers at Penn Medicine are looking at Parkinson's disease from all angles - ways to improve treatment methods for those currently battling the disease, understanding the root causes of disease, and identifying potential interventions to delay the onset of disease," said Matthew Stern, MD, professor of Neurology in the Perelman School of Medicine at the University of Pennsylvania and director of Penn's Parkinson's Disease and Movement Disorders Center. "We are persistent and eager to find better targets and … Continue reading →

The last time Annie Parkinson, 60, of Holden, had a drink or used drugs was June 13, 1982, when she was 28 years old. Ten years after she embarked on what she calls her long-term recovery, Ms. Parkinson, who worked for the former Norton Co., decided to change careers and become a therapist. She got her master's degree in therapy from Assumption College and now works at Community Healthlink in Worcester as the Suboxone coordinator for the Homeless Outreach & Advocacy Program. She also is an advocate for recovery and treatment. Her clients at HOAP are homeless people in recovery for addiction to opiates: heroin and prescription painkillers. Suboxone, or buprenorphine, blocks the opiate receptors in the brain so people can't get high. While the Suboxone program addresses opiate addictions specifically, Ms. Parkinson said the issues underlying addiction are universal. "I think a drug is a drug is a drug. It doesn't matter if you drink it, you smoke it, you shoot it, you eat it. I think they're all the same," she said. "They're all lethal in the end. They'll all use up your money and throw away your house and your job and everything else. They'll kill you." … Continue reading →

The last time Annie Parkinson, 60, of Holden, had a drink or used drugs was June 13, 1982, when she was 28 years old. Ten years after she embarked on what she calls her long-term recovery, Ms. Parkinson, who worked for the former Norton Co., decided to change careers and become a therapist. She got her master's degree in therapy from Assumption College and now works at Community Healthlink in Worcester as the Suboxone coordinator for the Homeless Outreach & Advocacy Program. She also is an advocate for recovery and treatment. Her clients at HOAP are homeless people in recovery for addiction to opiates: heroin and prescription painkillers. Suboxone, or buprenorphine, blocks the opiate receptors in the brain so people can't get high. While the Suboxone program addresses opiate addictions specifically, Ms. Parkinson said the issues underlying addiction are universal. "I think a drug is a drug is a drug. It doesn't matter if you drink it, you smoke it, you shoot it, you eat it. I think they're all the same," she said. "They're all lethal in the end. They'll all use up your money and throw away your house and your job and everything else. They'll kill you." … Continue reading →

The last time Annie Parkinson, 60, of Holden, had a drink or used drugs was June 13, 1982, when she was 28 years old. Ten years after she embarked on what she calls her long-term recovery, Ms. Parkinson, who worked for the former Norton Co., decided to change careers and become a therapist. She got her master's degree in therapy from Assumption College and now works at Community Healthlink in Worcester as the Suboxone coordinator for the Homeless Outreach & Advocacy Program. She also is an advocate for recovery and treatment. Her clients at HOAP are homeless people in recovery for addiction to opiates: heroin and prescription painkillers. Suboxone, or buprenorphine, blocks the opiate receptors in the brain so people can't get high. While the Suboxone program addresses opiate addictions specifically, Ms. Parkinson said the issues underlying addiction are universal. "I think a drug is a drug is a drug. It doesn't matter if you drink it, you smoke it, you shoot it, you eat it. I think they're all the same," she said. "They're all lethal in the end. They'll all use up your money and throw away your house and your job and everything else. They'll kill you." … Continue reading →

PHILADELPHIA A trio of studies from the Perelman School of Medicine at the University of Pennsylvania demonstrate new approaches to understanding, treating and potentially staving off Parkinson's disease (PD). Studies show that factors such as estrogen exposure and statin use have an impact on the onset of Parkinson's disease. And a new look at telemedicine demonstrates feasibility in providing care for Parkinson's patients using remote video visits to expand access and center care around the needs of Parkinson's patients. These studies and more will be presented at the American Academy of Neurologys 66th Annual Meeting at Philadelphias Pennsylvania Convention Center from April 26 to May 3, 2014. "Researchers at Penn Medicine are looking at Parkinson's disease from all angles - ways to improve treatment methods for those currently battling the disease, understanding the root causes of disease, and identifying potential interventions to delay the onset of disease," said Matthew Stern, MD, professor of Neurology in the Perelman School of Medicine at the University of Pennsylvania and director of Penn's Parkinson's Disease and Movement Disorders Center. "We are persistent and eager to find better targets and treatments to help patients with Parkinson's disease, which affects up to 1 million Americans and … Continue reading →

Researchers at Aarhus University, Denmark, have drawn up the most detailed 'image of the enemy' to date of one of the body's most important players in the development of Parkinson's disease. This provides much greater understanding of the battle taking place when the disease occurs -- knowledge that is necessary if we are to understand and treat the disease. However, it also raises an existential question because part of the conclusion is that we do not live forever! Parkinson's disease is one of the most common neurological disorders, with about 7000 people suffering from the disease in Denmark alone. There is no cure, and the symptoms continue to get worse. The disease occurs because different nerves in the brain die. These include the nerve cells that form dopamine, which is known as the brain's 'reward substance' and which also helps control our fine motor skills. A group of researchers from Aarhus University, the University of Southern Denmark (SDU) and the University of Cambridge has just published two studies in the prestigious Journal of the American Chemical Society (JACS) and Angewandte Chemie. These studies provide the best insight to date into the behaviour of a particular protein state that plays an … Continue reading →